Total Payments
$424,844
2024 Payments
$41,771
Companies
70
Transactions
1,718
Medicare Patients
23,953
Medicare Billing
$5.7M
Payment Breakdown by Category
Other$345,487 (81.3%)
Food & Beverage$40,767 (9.6%)
Consulting$28,726 (6.8%)
Travel$5,043 (1.2%)
Education$4,822 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $319,033 | 153 | 75.1% |
| Food and Beverage | $40,767 | 1,506 | 9.6% |
| Consulting Fee | $28,726 | 18 | 6.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $17,080 | 6 | 4.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,375 | 3 | 2.2% |
| Travel and Lodging | $5,043 | 19 | 1.2% |
| Education | $4,822 | 13 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $159,198 | 269 | $0 (2024) |
| Esperion Therapeutics, Inc. | $82,414 | 106 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $55,738 | 142 | $0 (2024) |
| Cardiovascular Systems Inc. | $34,056 | 196 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $32,884 | 150 | $0 (2024) |
| Cardinal Health 200 LLC | $18,253 | 41 | $0 (2021) |
| Amgen Inc. | $10,020 | 91 | $0 (2024) |
| Lilly USA, LLC | $7,468 | 13 | $0 (2024) |
| ARALEZ PHARMACEUTICALS US INC. | $6,412 | 14 | $0 (2018) |
| Novo Nordisk Inc | $4,787 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,771 | 197 | Boehringer Ingelheim Pharmaceuticals, Inc. ($26,935) |
| 2023 | $42,054 | 167 | Boehringer Ingelheim Pharmaceuticals, Inc. ($29,928) |
| 2022 | $65,143 | 212 | Boehringer Ingelheim Pharmaceuticals, Inc. ($23,854) |
| 2021 | $102,674 | 291 | Esperion Therapeutics, Inc. ($32,280) |
| 2020 | $60,157 | 233 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,467) |
| 2019 | $25,679 | 233 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,134) |
| 2018 | $14,541 | 135 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,997) |
| 2017 | $72,827 | 250 | Novartis Pharmaceuticals Corporation ($22,400) |
All Payment Transactions
1,718 individual payment records from CMS Open Payments — Page 1 of 69
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | ABSOLUTE PRO (Device) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Vascular | ||||||
| 12/19/2024 | Abbott Laboratories | ABSOLUTE PRO (Device) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Vascular | ||||||
| 12/19/2024 | BIOTRONIK INC. | Pulsar-18 T3 (Device) | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $0.76 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/16/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/13/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $32.47 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | BIOTRONIK INC. | Passeo-18 (Device) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $6.33 | General |
| Category: DIABETES | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 12/03/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Cardiology | ||||||
| 11/21/2024 | Boston Scientific Corporation | Ranger (Device) | Food and Beverage | In-kind items and services | $3.77 | General |
| Category: Ranger_PI | ||||||
| 11/20/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $3.79 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Obesity | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $9.93 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: DIABETES | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.65 | General |
| 10/31/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,480.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 10/23/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $123.43 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/23/2024 | BIOTRONIK INC. | Passeo-18 (Device) | Food and Beverage | In-kind items and services | $4.12 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 59 | 6,286 | 12,246 | $5.5M | $1.3M |
| 2022 | 55 | 5,865 | 12,018 | $5.2M | $1.4M |
| 2021 | 59 | 5,973 | 13,004 | $5.5M | $1.5M |
| 2020 | 55 | 5,829 | 13,619 | $5.2M | $1.5M |
Total Patients
23,953
Total Services
50,887
Medicare Billing
$5.7M
Procedure Codes
245
All Medicare Procedures & Services
245 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 33285 | Insertion of heart rhythm monitor under skin | Office | 2023 | 55 | 55 | $976,250 | $207,918 | 21.3% |
| 37225 | Removal of plaque in arteries of leg | Office | 2023 | 19 | 26 | $1.2M | $174,520 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 617 | 1,287 | $240,666 | $128,803 | 53.5% |
| 37229 | Removal of plaque in artery of leg, initial vessel | Office | 2023 | 13 | 14 | $644,000 | $112,966 | 17.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 256 | 256 | $208,640 | $99,074 | 47.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 456 | 1,102 | $170,810 | $73,153 | 42.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 298 | 303 | $257,550 | $50,447 | 19.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 239 | 956 | $81,260 | $40,800 | 50.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 359 | 553 | $84,990 | $38,309 | 45.1% |
| 36465 | Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | Office | 2023 | 26 | 28 | $171,640 | $32,631 | 19.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 169 | 178 | $84,550 | $29,306 | 34.7% |
| 37252 | Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | Office | 2023 | 24 | 32 | $144,000 | $27,589 | 19.2% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 36 | 36 | $112,500 | $26,507 | 23.6% |
| 36247 | Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | Office | 2023 | 24 | 35 | $44,275 | $24,679 | 55.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 220 | 228 | $57,065 | $24,464 | 42.9% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 252 | 260 | $28,325 | $22,210 | 78.4% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 94 | 97 | $50,925 | $20,297 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 105 | 112 | $31,360 | $15,226 | 48.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 695 | 1,278 | $124,122 | $14,724 | 11.9% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 84 | 90 | $42,750 | $14,699 | 34.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 99 | 144 | $27,360 | $14,190 | 51.9% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 23 | 28 | $35,000 | $12,388 | 35.4% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 162 | 342 | $64,410 | $11,101 | 17.2% |
| 36140 | Insertion of needle or tube into artery of arm or leg | Office | 2023 | 30 | 48 | $90,000 | $10,993 | 12.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $24,800 | $10,560 | 42.6% |
About Dr. Ziad Abbud, MD
Dr. Ziad Abbud, MD is a Specialist healthcare provider based in Neptune, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740373489.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ziad Abbud, MD has received a total of $424,844 in payments from pharmaceutical and medical device companies, with $41,771 received in 2024. These payments were reported across 1,718 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($319,033).
As a Medicare-enrolled provider, Abbud has provided services to 23,953 Medicare beneficiaries, totaling 50,887 services with total Medicare billing of $5.7M. Data is available for 4 years (2020–2023), covering 245 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Neptune, NJ
- Active Since 10/02/2006
- Last Updated 03/04/2016
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1740373489
Products in Payments
- JARDIANCE (Drug) $159,159
- NEXLIZET (Drug) $81,793
- FARXIGA (Drug) $54,196
- ENTRESTO (Drug) $31,013
- Diamondback Peripheral (Device) $17,861
- Peripheral Orbital Atherectomy System (Device) $11,709
- Repatha (Biological) $9,686
- PRADAXA (Drug) $7,457
- ZONTIVITY (Drug) $6,412
- Ozempic (Drug) $4,618
- Coronary Orbital Atherectomy System (Device) $3,826
- LEQVIO (Drug) $1,869
- BRILINTA (Drug) $1,385
- Xience Sierra Coronary Stent System (Device) $1,147
- XARELTO (Drug) $909.31
- NEXLETOL (Drug) $621.07
- Pulsar-18 T3 (Device) $615.28
- Impella (Device) $571.21
- OUTBACK LTD Re-Entry Catheter (Device) $561.27
- Xience Sierra Coronary Stent (Device) $549.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Neptune
Dr. Beverly Demchuk, M.d, M.D
Specialist — Payments: $14,067
Specialist $14,067
Dr. Ronald Matteotti, Md, MD
Specialist — Payments: $7,690
Specialist $7,690
Dr. Marc Colmer, M.d, M.D
Specialist — Payments: $5,311
Specialist $5,311
Dr. Alan Colicchio, M.d, M.D
Specialist — Payments: $390.39
Specialist $390.39
Eduardo Bautista, Md, MD
Specialist — Payments: $205.27
Specialist $205.27
Dr. Paul Silbert, Md, MD
Specialist — Payments: $107.64
Specialist $107.64